Compare IHS & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHS | IDYA |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.9B |
| IPO Year | 2021 | 2019 |
| Metric | IHS | IDYA |
|---|---|---|
| Price | $8.21 | $32.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | $8.11 | ★ $51.21 |
| AVG Volume (30 Days) | ★ 2.3M | 801.6K |
| Earning Date | 03-16-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $218,710,000.00 |
| Revenue This Year | $3.90 | N/A |
| Revenue Next Year | $2.64 | $191.08 |
| P/E Ratio | $5.85 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $4.21 | $13.45 |
| 52 Week High | $8.95 | $39.28 |
| Indicator | IHS | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 54.47 | 46.19 |
| Support Level | $7.82 | $29.15 |
| Resistance Level | $8.21 | $33.64 |
| Average True Range (ATR) | 0.10 | 1.40 |
| MACD | 0.00 | -0.24 |
| Stochastic Oscillator | 60.00 | 43.37 |
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.